Avenue Therapeutics reports FY2023 net loss of $10.5M; AJ201 Phase 1b/2a enrollment complete, topline data Q2 2024

AVENUE THERAPEUTICS, INC.

Net loss of $10.5M ($0.98 per share) vs $3.6M loss in FY2022; cash $1.8M as of Dec 31, 2023.
Completed enrollment in AJ201 Phase 1b/2a for SBMA (25 patients); topline data expected Q2 2024.
Reached final agreement with FDA on Phase 3 safety study protocol for IV tramadol; aims to initiate pending financing.
Nasdaq granted extension to May 20, 2024 to meet continued listing requirements.
Raised $5.0M gross in January 2024 via warrant inducement.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

AVENUE THERAPEUTICS, INC. reported the fiscal year ended December 31, 2023 results: net income Net loss for the full year 2023 was $10.5 million, or $0.98 per share, compared to a net loss of $3.6 million, or $1.63, EPS $0.98 per share.

Period: the fiscal year ended December 31, 2023
Net income: Net loss for the full year 2023 was $10.5 million, or $0.98 per share, compared to a net loss of $3.6 million, or $1.63
EPS: $0.98 per share
Result: reported results

Exact text from the filing

Net loss for the full year 2023 was $10.5 million, or $0.98 per share, compared to a net loss of $3.6 million, or $1.63 per share, in 2022.

View on SEC.gov

Browse all earnings releases →

AVENUE THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001104659-24-035544

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.